Skip to main content
Sputum anti-CCP the new diagnostic test in at-risk RA?'

Dr. Aurelie Najm ( @AurelieRheumo) discusses abstract 0533 a

Dr. John Cush RheumNow

3 years 11 months ago
Sputum anti-CCP the new diagnostic test in at-risk RA?' Dr. Aurelie Najm ( @AurelieRheumo) discusses abstract 0533 at #ACR22. https://t.co/DNKVmPjmh9 https://t.co/b5x26PzzS5
Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial

Dr. Michael Putman interviews Dr. Robert Speira about a

Dr. John Cush RheumNow

3 years 11 months ago
Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at #ACR22. https://t.co/nJAOBDC8KX https://t.co/Tgls8O4AVC
Why Clinical Trials?
Interstitial lung disease is common in RA, occurring in approximately 8% of RA patients. It is associated with a poor prognosis, and a median survival of 3 years. This important condition has often been neglected within the spectrum of RA research. That is changing, with excellent research initiatives presented at ACR22. I am going to highlight two select abstracts from Monday’s dedicated RA-ILD session.
Peresolimab for RA: Phase 2a Results
Conferences are held for the purposes of sharing ideas, developing new relationships, and collaborating on future research. The American College of Rheumatology (ACR) Convergence 2022 meeting embodies all these ideals by offering both in-person and virtual attendance options. However, when a conference ends, what happens to the attendees? Will they remember what they learned? Will they incorporate new ideas into their practice?
“Hey PRESTO!” – Early identification of psoriatic arthritis

The past decade has seen the management of psoriatic

Dr. John Cush RheumNow

3 years 11 months ago
“Hey PRESTO!” – Early identification of psoriatic arthritis The past decade has seen the management of psoriatic arthritis (PsA) transform, with our rich therapeutic armamentarium truly revolutionising patient outcomes. https://t.co/FJNX3mGCoy https://t.co/Whd8QKwmkU
Effect of voclosporin in class V lupus nephritis

Dr. Yusof ( @Yuz6Yusof) discusses abstract 0355 presented at #ACR22.

Dr. John Cush RheumNow

3 years 11 months ago
Effect of voclosporin in class V lupus nephritis Dr. Yusof ( @Yuz6Yusof) discusses abstract 0355 presented at #ACR22. Abstract 0355: Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results from the AURORA 2 Continuation Study https://t.co/v716QGx73g https://t.co/ANTOEDAAHt
The CONSUL Trial: Ankylosing Spondylitis

Dr. Sheila Reyes ( @RHEUMarampa) discusses abstract 0546 presented at #ACR22.

Dr. John Cush RheumNow

3 years 11 months ago
The CONSUL Trial: Ankylosing Spondylitis Dr. Sheila Reyes ( @RHEUMarampa) discusses abstract 0546 presented at #ACR22. https://t.co/DXTn3XfEzC https://t.co/pbORtBsRm2
JAK vs TNF inhibitor Infections in RA

Dr. David Liew ( @drdavidliew) discusses abstract 0302 at #ACR22 Convergence. A

Dr. John Cush RheumNow

3 years 11 months ago
JAK vs TNF inhibitor Infections in RA Dr. David Liew ( @drdavidliew) discusses abstract 0302 at #ACR22 Convergence. Abstract 0302: Risk of Infections Between JAK Inhibitors and TNF Inhibitors Among Patients with Rheumatoid Arthritis https://t.co/GsOsWtuT7v https://t.co/GloKEcB75L
Does BASDAI work for women?

In Abstract 0406 S. Maguire et al sought to understand if BASDAI and BASFI captured diseas

Dr. John Cush RheumNow

3 years 11 months ago
Does BASDAI work for women? In Abstract 0406 S. Maguire et al sought to understand if BASDAI and BASFI captured disease activity and quality of life in female axSpA patients. Read more from Dr. Rachel Tate ( @uptoTate ) #ACR22 https://t.co/yWzdRMPgpp https://t.co/YrMsAYbAWN
RA Topic Panel: ACR22
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
×